
Cristian Tomasetti

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8749690/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science, 2018, 359, 926-930.	12.6	1,872
2	Variation in cancer risk among tissues can be explained by the number of stem cell divisions. Science, 2015, 347, 78-81.	12.6	1,561
3	Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Science Translational Medicine, 2016, 8, 346ra92.	12.4	1,036
4	Stem cell divisions, somatic mutations, cancer etiology, and cancer prevention. Science, 2017, 355, 1330-1334.	12.6	803
5	Cancer-Associated Mutations in Endometriosis without Cancer. New England Journal of Medicine, 2017, 376, 1835-1848.	27.0	451
6	Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 10202-10207.	7.1	438
7	Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer. JAMA Oncology, 2019, 5, 1710.	7.1	383
8	Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention. Science, 2020, 369, .	12.6	351
9	Half or more of the somatic mutations in cancers of self-renewing tissues originate prior to tumor initiation. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 1999-2004.	7.1	348
10	Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer. New England Journal of Medicine, 2022, 386, 2261-2272.	27.0	337
11	Only three driver gene mutations are required for the development of lung and colorectal cancers. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 118-123.	7.1	325
12	Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study. Gut, 2019, 68, 663-671.	12.1	234
13	Genome-wide quantification of rare somatic mutations in normal human tissues using massively parallel sequencing. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 9846-9851.	7.1	178
14	Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers. Science Translational Medicine, 2018, 10, .	12.4	178
15	Prognostic Potential of Circulating Tumor DNA Measurement in Postoperative Surveillance of Nonmetastatic Colorectal Cancer. JAMA Oncology, 2019, 5, 1118.	7.1	152
16	A multimodality test to guide the management of patients with a pancreatic cyst. Science Translational Medicine, 2019, 11, .	12.4	129
17	Non-invasive detection of urothelial cancer through the analysis of driver gene mutations and aneuploidy. ELife, 2018, 7, .	6.0	118
18	Role of symmetric and asymmetric division of stem cells in developing drug resistance. Proceedings of the United States of America, 2010, 107, 16766-16771.	7.1	90

CRISTIAN TOMASETTI

#	Article	IF	CITATIONS
19	Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study. PLoS Medicine, 2021, 18, e1003620.	8.4	88
20	Genomic landscape and evolutionary trajectories of ovarian cancer precursor lesions. Journal of Pathology, 2019, 248, 41-50.	4.5	84
21	Prognostic significance of postsurgery circulating tumor <scp>DNA</scp> in nonmetastatic colorectal cancer: Individual patient pooled analysis of three cohort studies. International Journal of Cancer, 2021, 148, 1014-1026.	5.1	77
22	Cell division rates decrease with age, providing a potential explanation for the age-dependent deceleration in cancer incidence. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 20482-20488.	7.1	63
23	Cancer risk: Role of environment—Response. Science, 2015, 347, 729-731.	12.6	59
24	An elementary approach to modeling drug resistance in cancer. Mathematical Biosciences and Engineering, 2010, 7, 905-918.	1.9	52
25	Assessing aneuploidy with repetitive element sequencing. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 4858-4863.	7.1	50
26	Incidence and distribution of UroSEEK gene panel in a multi-institutional cohort of bladder urothelial carcinoma. Modern Pathology, 2019, 32, 1544-1550.	5.5	45
27	Revisiting the tumorigenesis timeline with a data-driven generative model. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 857-864.	7.1	44
28	Role of stem-cell divisions in cancer risk. Nature, 2017, 548, E13-E14.	27.8	42
29	Detection of low-frequency DNA variants by targeted sequencing of the Watson and Crick strands. Nature Biotechnology, 2021, 39, 1220-1227.	17.5	40
30	Non-steroidal anti-inflammatory drugs, intravenous fluids, pancreatic stents, or their combinations for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a systematic review and network meta-analysis. The Lancet Gastroenterology and Hepatology, 2021, 6, 733-742.	8.1	31
31	Mutated clones are the new normal. Science, 2019, 364, 938-939.	12.6	28
32	The (not so) immortal strand hypothesis. Stem Cell Research, 2015, 14, 238-241.	0.7	22
33	Serial circulating tumor DNA (ctDNA) analysis as a prognostic marker and a real-time indicator of adjuvant chemotherapy (CT) efficacy in stage III colon cancer (CC) Journal of Clinical Oncology, 2018, 36, 3516-3516.	1.6	19
34	The potential role of circulating tumor DNA (ctDNA) in the further investigation of colorectal cancer patients with nonspecific findings on standard investigations. International Journal of Cancer, 2019, 145, 540-547.	5.1	15
35	On the slope of the regression between stem cell divisions and cancer risk, and the lack of correlation between stem cell divisions and environmental factors-associated cancer risk. PLoS ONE, 2017, 12, e0175535.	2.5	12
36	Supervised mutational signatures for obesity and other tissue-specific etiological factors in cancer. ELife, 2021, 10, .	6.0	12

CRISTIAN TOMASETTI

#	Article	IF	CITATIONS
37	On the Probability of Random Genetic Mutations for Various Types of Tumor Growth. Bulletin of Mathematical Biology, 2012, 74, 1379-1395.	1.9	11
38	An argument for mechanism-based statistical inference in cancer. Human Genetics, 2015, 134, 479-495.	3.8	9
39	A new hypothesis: imatinib affects leukemic stem cells in the same way it affects all other leukemic cells. Blood Cancer Journal, 2011, 1, e19-e19.	6.2	7
40	Evaluating the impact of multicancer early detection testing on health and economic outcomes: Toward a decision modeling strategy. Cancer, 2022, 128, 892-908.	4.1	7
41	Drug Resistance. Advances in Experimental Medicine and Biology, 2014, 844, 303-316.	1.6	6
42	Adjuvant chemotherapy guided by circulating tumor DNA analysis in stage II colon cancer: The randomized DYNAMIC trial Journal of Clinical Oncology, 2022, 40, LBA100-LBA100.	1.6	5
43	Circulating tumor DNA as a prognostic biomarker in early stage pancreatic cancer Journal of Clinical Oncology, 2018, 36, e16206-e16206.	1.6	4
44	Why tyrosine kinase inhibitor resistance is common in advanced gastrointestinal stromal tumors. F1000Research, 2013, 2, 152.	1.6	2
45	1124 A MULTI-MODALITY TEST TO GUIDE THE MANAGEMENT OF PATIENTS WITH PANCREATIC CYSTS. Gastrointestinal Endoscopy, 2019, 89, AB143-AB144.	1.0	1
46	Stochastic Modelling of Multiple Random Genetic Mutations Under the Cancer Stem Cell Hypothesis. Mathematical Population Studies, 2012, 19, 200-213.	2.2	0
47	The Average Baseline BCR-ABL Levels Are Significantly Higher in Patients with Resistance to Dasatinib As First-Line Treatment for Early Chronic Phase Chronic Myeloid Leukemia. Blood, 2012, 120, 4436-4436.	1.4	0